162 related articles for article (PubMed ID: 30856589)
1. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy.
Domínguez-Ríos R; Sánchez-Ramírez DR; Ruiz-Saray K; Oceguera-Basurto PE; Almada M; Juárez J; Zepeda-Moreno A; Del Toro-Arreola A; Topete A; Daneri-Navarro A
Colloids Surf B Biointerfaces; 2019 Jun; 178():199-207. PubMed ID: 30856589
[TBL] [Abstract][Full Text] [Related]
2. Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles.
Colzani B; Pandolfi L; Hoti A; Iovene PA; Natalello A; Avvakumova S; Colombo M; Prosperi D
Int J Nanomedicine; 2018; 13():957-973. PubMed ID: 29491709
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
4. Development and characterization of hyaluronic acid modified PLGA based nanoparticles for improved efficacy of cisplatin in solid tumor.
Alam N; Koul M; Mintoo MJ; Khare V; Gupta R; Rawat N; Sharma PR; Singh SK; Mondhe DM; Gupta PN
Biomed Pharmacother; 2017 Nov; 95():856-864. PubMed ID: 28903181
[TBL] [Abstract][Full Text] [Related]
5. Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity.
Houdaihed L; Evans JC; Allen C
Pharm Res; 2020 Jan; 37(3):39. PubMed ID: 31965330
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies.
Koopaei MN; Dinarvand R; Amini M; Rabbani H; Emami S; Ostad SN; Atyabi F
Int J Nanomedicine; 2011; 6():1903-12. PubMed ID: 21931485
[TBL] [Abstract][Full Text] [Related]
7. Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells.
Caputo TM; Barisciano G; Mulè C; Cusano AM; Aliberti A; Muccillo L; Colantuoni V; Sabatino L; Cusano A
Int J Nanomedicine; 2023; 18():6999-7020. PubMed ID: 38034948
[TBL] [Abstract][Full Text] [Related]
8. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer.
Mi Y; Zhao J; Feng SS
J Control Release; 2013 Aug; 169(3):185-92. PubMed ID: 23403395
[TBL] [Abstract][Full Text] [Related]
9. Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization.
Martínez-Jothar L; Beztsinna N; van Nostrum CF; Hennink WE; Oliveira S
Mol Pharm; 2019 Apr; 16(4):1633-1647. PubMed ID: 30817164
[TBL] [Abstract][Full Text] [Related]
10. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
Cirstoiu-Hapca A; Bossy-Nobs L; Buchegger F; Gurny R; Delie F
Int J Pharm; 2007 Mar; 331(2):190-6. PubMed ID: 17196347
[TBL] [Abstract][Full Text] [Related]
11. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
13. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy.
Wang H; Jia D; Yuan D; Yin X; Yuan F; Wang F; Shi W; Li H; Zhu LM; Fan Q
J Nanobiotechnology; 2021 May; 19(1):138. PubMed ID: 33985511
[TBL] [Abstract][Full Text] [Related]
14. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
15. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
16. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
17. Photochemical activation of MH3-B1/rGel: a HER2-targeted treatment approach for ovarian cancer.
Bull-Hansen B; Berstad MB; Berg K; Cao Y; Skarpen E; Fremstedal AS; Rosenblum MG; Peng Q; Weyergang A
Oncotarget; 2015 May; 6(14):12436-51. PubMed ID: 26002552
[TBL] [Abstract][Full Text] [Related]
18. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
19. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
20. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
